Apex-3Retatrutide
Triple agonist. Three pathways. One injection.
About
What it is
Retatrutide hits GLP-1, GIP, and glucagon receptors simultaneously — the first triple agonist for weight management. Early trial data shows it outperforms dual agonists, with some participants losing over 24% of body weight.
How it works
Retatrutide activates three incretin receptors simultaneously: GLP-1 (appetite suppression), GIP (insulin sensitivity and fat metabolism), and glucagon (energy expenditure and fat oxidation). The triple mechanism produces stronger metabolic effects than dual or single agonists.
Benefits
Who it's for
What to expect
Week 1–2
Starting dose. Appetite begins decreasing. Mild GI adjustment possible.
Week 4–6
Titration continues. Appetite suppression and energy expenditure both increase.
Week 8–12
Significant weight loss. Triple mechanism drives enhanced fat metabolism.
Week 24+
Clinical trials show 24%+ average body weight reduction at full dose.
Safety & tolerability
Retatrutide is in advanced clinical trials with promising safety data. Side effects are similar to other incretin agonists — primarily GI-related during titration. Our care team uses a gradual titration protocol and monitors your progress throughout. Compounded from pharmaceutical-grade API and independently tested.
How we compound
Single-source API
Every peptide is sourced from one vetted pharmaceutical-grade supplier — no blending from multiple sources.
Third-party tested
Independent labs verify purity, potency, sterility, and endotoxin levels before any batch is released.
Care team reviewed
A real person reviews your profile, your protocol, and your progress. Not an algorithm.
Weight Loss
Apex-3Retatrutide
Every protocol is reviewed by our care team before it ships. Questions? Learn more
$279/mo
